

REGISTERED NUMBER: 10040765 (England and Wales)

Financial Statements for the Period 3 March 2016 to 31 March 2017

for

Fluid Pharma Ltd



Fluid Pharma Ltd (by shares) (Registered number: 10040765)

Contents of the Financial Statements
for the period 3 March 2016 to 31 March 2017

	Page
Company Information	1
Balance Sheet	2

Fluid Pharma Ltd (by shares)

Company Information

for the period 3 March 2016 to 31 March 2017

DIRECTORS:

IP2IPO Services Limited
Dr F Liu
Dr D Murnane

SECRETARY:

IP2IPO Services Limited

REGISTERED OFFICE:

Leeds Innovation Centre
103 Clarendon road
Leeds
LS2 9DF

REGISTERED NUMBER:

10040765 (England and Wales)

ACCOUNTANTS:

Atraxa Consulting Limited
Brooke's Mill
Armitage Bridge
Huddersfield
West Yorkshire
HD4 7NR

Fluid Pharma Ltd (by shares) (Registered number: 10040765)

Balance Sheet

31 March 2017

	£
CALLED UP SHARE CAPITAL NOT PAID	26
CURRENT ASSETS	204,990
CREDITORS	
Amounts falling due within one year	(1,194)
NET CURRENT ASSETS	203,796
TOTAL ASSETS LESS CURRENT LIABILITIES	203,822
CAPITAL AND RESERVES	203,822

NOTE TO THE FINANCIAL STATEMENTS

1. OTHER FINANCIAL COMMITMENTS

On 19 May 2016 the company entered into a collaboration agreement with UH Ventures Limited, a subsidiary of the University of Hertfordshire under which UH Ventures will carry out research and development on behalf of the company. At 31 March 2017, the company was committed to a maximum remaining cost under this agreement of £248,000.

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2017.


The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 07 Nov 2017 and were signed on its behalf by:



IP2IPO Services Limited - Director

REGISTERED NUMBER: 10040765 (England and Wales)

Financial Statements for the Period 3 March 2016 to 31 March 2017

for

Fluid Pharma Ltd

Fluid Pharma Ltd (by shares) (Registered number: 10040765)

Contents of the Financial Statements
for the period 3 March 2016 to 31 March 2017

	Page
Company Information	1
Balance Sheet	2

Fluid Pharma Ltd (by shares)

Company Information

for the period 3 March 2016 to 31 March 2017

DIRECTORS:

IP2IPO Services Limited
Dr F Liu
Dr D Murnane

SECRETARY:

IP2IPO Services Limited

REGISTERED OFFICE:

Leeds Innovation Centre
103 Clarendon road
Leeds
LS2 9DF

REGISTERED NUMBER:

10040765 (England and Wales)

ACCOUNTANTS:

Atraxa Consulting Limited
Brooke's Mill
Armitage Bridge
Huddersfield
West Yorkshire
HD4 7NR

Fluid Pharma Ltd (by shares) (Registered number: 10040765)

Balance Sheet

31 March 2017

	£
CALLED UP SHARE CAPITAL NOT PAID	26
CURRENT ASSETS	204,990
CREDITORS	
Amounts falling due within one year	(1,194)
NET CURRENT ASSETS	203,796
TOTAL ASSETS LESS CURRENT LIABILITIES	203,822
CAPITAL AND RESERVES	203,822

NOTE TO THE FINANCIAL STATEMENTS

1. OTHER FINANCIAL COMMITMENTS

On 19 May 2016 the company entered into a collaboration agreement with UH Ventures Limited, a subsidiary of the University of Hertfordshire under which UH Ventures will carry out research and development on behalf of the company. At 31 March 2017, the company was committed to a maximum remaining cost under this agreement of £248,000.

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2017.


The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 07 Nov 2017 and were signed on its behalf by:



IP2IPO Services Limited - Director